We found previously that CD4+ iNKT cells exert robust antileukemia effects by themselves: BALB/c mice that were challenged with luciferase-expressing lymphoma cells showed a significantly improved survival after allogeneic HCT with T cell-depleted bone marrow cells and adoptive transfer of CD4+ iNKT cells both from C57BL/6 mice (3). Here, CD4 is linked to lymphoma.